Florbetapir F 18 (brand name Amyvid) is a radioactive diagnostic agent used in positron emission tomography (PET) imaging to detect amyloid-beta (Aβ) plaques in the brain. It received FDA approval in 2012 for use in patients with cognitive impairment being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline. Florbetapir represents a major advancement in the in vivo visualization of one of the hallmark pathological features of AD, enabling clinicians to confirm or exclude amyloid pathology before the onset of overt dementia. [1]
Florbetapir (chemical name: (E)-4-(2-(2-(2-[18F]fluoroethoxy)ethoxy)ethoxy)vinyl)-N-methylbenzene) is a stilbene derivative that binds with high affinity and specificity to aggregated amyloid-beta plaques. The binding characteristics are critical to its clinical utility:
The stilbene core of florbetapir allows it to bind to the β-sheet structure common to all amyloid fibrils. The binding site is distinct from that occupied by other amyloid tracers like Pittsburgh compound B (PiB), which explains differences in kinetic properties and regional uptake patterns. The ethylene glycol chain improves lipophilicity to optimize brain penetration while the fluorine-18 label provides the radioactive signal detectable by PET cameras.
The standard imaging protocol involves:
The recommended scan acquisition begins 30 minutes after injection with a 10-minute emission acquisition. The entire procedure from injection to scan completion takes approximately 60-70 minutes. [3]
Florbetapir PET serves multiple clinical purposes in AD evaluation:
The clinical utility is highest in patients with unclear diagnosis after standard neuropsychological evaluation. Studies show that amyloid PET changes diagnostic confidence in 50-70% of cases and frequently alters clinical management. [4]
Florbetapir enables detection of amyloid pathology in the preclinical phase, years before clinical symptoms manifest:
Florbetapir has become indispensable for clinical trial design:
The availability of amyloid PET allowed the development of anti-amyloid antibodies (lecanemab, donanemab) by enabling proper patient selection and biomarker-based outcome assessment. Studies using florbetapir showed that amyloid plaque removal correlates with clinical benefit in trials. [7]
The visual read remains the standard clinical interpretation method:
| Result | Interpretation | Clinical Implication |
|---|---|---|
| Positive | Amyloid plaques detected above threshold | Consistent with AD pathophysiology; supports AD diagnosis |
| Negative | No amyloid plaques detected | AD pathophysiology less likely; consider alternative diagnoses |
Inter-reader agreement for visual reads is excellent (kappa > 0.90) when readers follow standardized training. Regional patterns are also assessed, with occipital uptake being a reliable internal control.
Quantitative SUVr analysis provides continuous measures of amyloid burden:
SUVr Calculation:
Centiloid Scale:
The Centiloid scale was developed to standardize amyloid measurements across tracers and centers:
The Centiloid scale enables cross-study comparison and longitudinal monitoring. [8]
Amyloid deposition follows characteristic patterns:
This staging correlates with the Thal phases of amyloid deposition and provides prognostic information.
Florbetapir demonstrates excellent diagnostic accuracy:
| Metric | Performance | Notes |
|---|---|---|
| Sensitivity | 92-96% | For detecting histologically confirmed Aβ plaques [9] |
| Specificity | 78-90% | For distinguishing AD from non-AD subjects |
| Positive Predictive Value | High | Depends on pre-test probability |
| Negative Predictive Value | Very High | >95% at typical prevalence |
| AUC | 0.94-0.97 | For distinguishing AD from controls |
Multiple studies have validated florbetapir against postmortem neuropathology:
The validation studies established the pathological basis for florbetapir signal and confirmed it directly reflects the neuropathological substrate of AD. [9:1]
Three FDA-approved amyloid PET tracers are available, all using F-18 labeling:
| Property | Florbetapir (Amyvid) | Florbetaben (Neuraceq) | Flutemetamol (Vizamyl) |
|---|---|---|---|
| FDA Approval | 2012 | 2014 | 2013 |
| Company | Eli Lilly | Piramal/GE | GE Healthcare |
| Half-life | 110 min | 110 min | 110 min |
| Key Strength | Widely available | Excellent specificity | Strong clinical validation |
| Recommended Scan Time | 30-50 min | 90-110 min | 90-110 min |
| Visual Read Training | Standardized | Required | Required |
All three tracers show excellent correlation with each other (r > 0.90) and with neuropathology. Choice often depends on local availability and protocol preferences. [10] [11]
Several conditions can cause positive amyloid PET despite AD not being the primary pathology:
The clinical interpretation must consider these possibilities, especially in older patients with atypical presentations.
Negative scans do not definitively exclude AD:
The clinical context is essential - a negative scan is more meaningful in older patients with typical AD presentation than in younger patients with atypical cognitive symptoms.
Florbetapir PET is covered by Medicare (Part B) under specific conditions:
Coverage requires documentation of:
Most private insurers follow similar coverage criteria, though prior authorization is typically required. Some insurers have specific amyloid PET policies with detailed documentation requirements.
Florbetapir PET serves as the "A" (Amyloid) biomarker in the AT(N) classification framework:
| AT(N) Component | Biomarker | Florbetapir Role |
|---|---|---|
| A | Amyloid | Florbetapir PET confirms amyloid pathology |
| T | Tau | CSF p-tau or tau PET (e.g., flortaucipir) |
| (N) | Neurodegeneration | FDG-PET, MRI atrophy, CSF t-tau |
This integrated biomarker approach enables more precise diagnosis and staging of AD. [8:1]
Florbetapir results should be interpreted alongside:
The combination of amyloid PET with these biomarkers provides comprehensive pathological characterization and enables accurate differential diagnosis.
The field is moving toward earlier identification and intervention, with amyloid PET serving as the gatekeeper for anti-amyloid therapeutic decisions. [@ mattke2021]
Clark CM, et al. Florbetapir F18 PET imaging of amyloid pathology in Alzheimer disease and mild cognitive impairment. Neurology. 2012. ↩︎
Wong DF, et al. In vivo labeling of amyloid in Alzheimer's disease with F-18 florbetapir (AV-45). 2010. ↩︎
Agarwal R, et al. Florbetapir F 18: A Review of its Use in Amyloid PET Imaging. 2019. ↩︎
Hatton K, et al. Amyloid imaging with 18F-florbetapir in preclinical and prodromal Alzheimer's disease. 2015. ↩︎
Ryman DC, et al. Florbetapir PET: Predicting progression from normal cognition to mild cognitive impairment. 8. ↩︎
Chen J, et al. Amyloid PET in early-onset dementia: a systematic review and meta-analysis. 2021. ↩︎
Donahue M, et al. Amyloid PET imaging in anti-amyloid beta antibody trials. 2020. ↩︎
Janelidze S, et al. CSF biomarkers of amyloid and tau pathology predict rate of cognitive decline. 2020. ↩︎ ↩︎
Johnson KA, et al. Florbetapir analysis of neuropathological correlates of amyloid PET. 2013. ↩︎ ↩︎
Sabri O, et al. Florbetaben F18 PET: Global European multicenter phase III study. 2015. ↩︎
Suppiah S, et al. FDA-approved (2018) amyloid PET radiopharmaceuticals: an overview. 2019. ↩︎ ↩︎